TC Biopharm (Holdings) Plc
TCBPY
$0.335
$0.026.35%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.47M | 8.52M | 7.56M | 8.03M | 8.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 65.70K | -34.60K | -136.70K | -19.60K | -1.00K |
| Total Operating Expenses | 16.41M | 15.68M | 14.94M | 16.97M | 17.68M |
| Operating Income | -16.41M | -15.68M | -14.94M | -16.97M | -17.68M |
| Income Before Tax | -16.39M | -15.86M | -15.34M | -11.83M | -8.73M |
| Income Tax Expenses | -835.90K | -798.50K | -761.30K | -1.00M | -1.35M |
| Earnings from Continuing Operations | -15.56 | -15.06 | -14.58 | -10.83 | -7.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.56M | -15.06M | -14.58M | -10.83M | -7.39M |
| EBIT | -16.41M | -15.68M | -14.94M | -16.97M | -17.68M |
| EBITDA | -15.85M | -15.06M | -14.27M | -16.25M | -16.90M |
| EPS Basic | -607.22K | -505.58K | -402.30K | -- | -- |
| Normalized Basic EPS | -100.26 | -83.37 | -66.21 | -- | -- |
| EPS Diluted | -610.69K | -507.33K | -402.30K | -- | -- |
| Normalized Diluted EPS | -100.26 | -83.37 | -66.21 | -- | -- |
| Average Basic Shares Outstanding | 369.90K | 197.40K | 24.90K | -- | -- |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |